Company
Melbourne, VIC
Every investor coverage indicates participated in a round Ludwig Institute for Cancer Research raised.
Companies Ludwig Institute for Cancer Research acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Antony “Tony” Burgess | Director (former) | Synthesis BioVentures |
| Prof Andrew Wilks | Forbes Australia, Synthesis BioVentures |
Stories naming Ludwig Institute for Cancer Research. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.